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Background: Elobixibat is a minimally absorbed ileal bile acid (BA) transporter (IBAT) inhibitor in development
against chronic constipation (CC) and constipation-predominant Irritable Bowel Syndrome (IBS-C). CC is associated
with an increased risk for cardiovascular disease and type2 diabetes mellitus. The objectives of this study were to
evaluate metabolic effects of elobixibat. Effects on plasma lipids and BA synthesis were evaluated utilizing a 4-week,
placebo-controlled study in patients with dyslipidemia while changes of glucagon-like peptide-1 (GLP-1) by
elobixibat was assayed in samples from a 14 day high-dose elobixibat study in patients with CC.
Methods: Thirty-six dyslipidemic patients, 21 females, mean age 63 years, were randomized to 2.5 mg or 5 mg
elobixibat or placebo once daily for four weeks. The primary endpoint was the change in low density lipoprotein
(LDL) cholesterol. Secondary endpoints included other lipid parameters and serum 7α-hydroxy-4-cholesten-3-one
(C4), a marker of BA (bile acid) synthesis. Another study, in 36 patients with CC treated with high dose elobixibat;
15 mg or 20 mg/day or placebo for 14 days, was evaluated for changes in GLP-1.
Results: In the dyslipidemia study LDL cholesterol was reduced by 7.4 % (p = 0.044), and the LDL/HDL ratio was
decreased by 18 % (p = 0.004). Serum C4 increased, indicating that BA synthesis was induced. No serious adverse
events were recorded. In the CC study, GLP-1 increased significantly in both the 15 mg (20.7 ± 2.4 pmol/L; p = 0.03)
and the 20 mg group (25.6 ± 4.9 pmol/L; p = 0.02).
Conclusions: Elobixibat reduces LDL cholesterol and LDL/HDL ratio and increase circulating peak GLP-1 levels, the
latter in line with increased intestinal BA mediated responses in humans.
Trial registrations: ClinicalTrial.gov: NCT01069783 and NCT01038687.
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A key step in bile acid (BA) homeostasis is the active up-
take of BAs through the apical enterocyte membranes of
the distal ileum by the ileal apical sodium-dependent bile
acid transporter (IBAT or ASBT [apical sodium-dependent
BA transporter]). Inhibition of IBAT reduces the active ileal
absorption of BAs, increasing the content of BAs in the
colon, thereby stimulating colonic secretion and motility
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(CC) [3–5]. In addition to their role as detergents facilitat-
ing dietary lipid absorption, BAs modulate various meta-
bolic events after binding to specific BA receptors such as
the farnesoid x receptor (FXR) and the G-protein-coupled
receptor TGR5 [6, 7]. Thus, BAs regulate glucose and lipid
metabolism as well as energy expenditure [6].
When ileal BA absorption decreases, fecal loss of BAs in-
creases resulting in an upregulation of hepatic BA synthesis
to maintain BA homeostasis. BA synthesis can be moni-
tored from the level of C4 (7α-hydroxy-4-cholesten-3-one)
in serum, a marker for the enzymatic activity of cholesterol
7α-hydroxylase [8], the rate-limiting enzyme in BA synthe-
sis. Cholesterol is precursor in the synthesis of BAs. Induc-
tion of BA synthesis depletes hepatic cholesterol stores,
which is compensated for through increased hepaticrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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number of hepatic low density lipoprotein (LDL) receptors
that subsequently reduce plasma LDL cholesterol levels.
How BAs modulate glucose homeostasis has lately gained
renewed interest with studies claiming increased release of
glucagon-like peptide-1 (GLP-1) from the intestine follow-
ing administration with a bile acid binding sequestrant [9]
and after rectal administration of taurocholate [10]. Also
the mode of action of the hypoglycemic agent metformin
has been suggested to include decreased intestinal bile acid
absorption [11–13].
Elobixibat is a selective and partial inhibitor of IBAT
with a novel and unique mechanism of action. After oral
administration, systemic exposure is minimal [14]. In
three studies in patients with CC [3–5], elobixibat en-
hanced colonic transit, thereby improving symptoms of
CC such as increased stool frequency concomitant with
reduced straining, bloating and hard stools.
The aim of the present investigation was to evaluate
metabolic responses of elobixibat. For this purpose, the
level of BA synthesis and serum lipid profiles were moni-
tored in dyslipidemic patients treated with elobixibat for
28 days. In addition, we also evaluated whether such treat-
ment may increase serum levels of the incretin GLP-1 in a
study of CC patients treated with elobixibat at high dose.
Methods
The Dyslipidemia study
Study design, baseline eligibility, randomization and
medication
This was a single-center, randomized, parallel-group,
double-blind, placebo-controlled, two dose, pharmaco-
dynamic study evaluating the effects of elobixibat in
dyslipidemic patients. Dyslipidemia was defined as
having serum total cholesterol levels >5.5 mmol/L
(213 mg/dL). The study was approved by the Linköp-
ing University Regional Ethics Review Board. It was
performed from February 2010 (first signed informed
consent) to July 2010 (last patient visit).
After informed consent was obtained, patients entered a
14 day screening period when routine blood tests, urinaly-
sis, and pregnancy tests were made and demographic data
collected. If screening assessments provided proof of eligi-
bility, the patient was randomized. Patients were random-
ized to receive one tablet daily containing 2.5 mg
elobixibat, 5 mg elobixibat or matching placebo for 28 con-
secutive days. A randomization list was generated by an
independent statistician prior to the study and the assign-
ments were concealed from all study personal until the
study was closed and the final data transmitted to the
study statistician for analysis. All clinical and laboratory
study personnel were blinded throughout the study until
data were locked and analyzed. Safety was monitored
throughout the study. At Day 14 of the treatment period,a visit to document health status, adverse events (AEs)
and for blood sampling took place and at the end of the
treatment period a similar visit was scheduled. Fourteen
days after last day of treatment, a follow-up visit was
conducted.
Study medication
The IBAT Inhibitor elobixibat is a small molecule
known to be a partial inhibitor of the ileal BA trans-
porter (IBAT). The effects of elobixibat on GI motility
and fecal output show an increase in fecal output identi-
fied at the lowest dose (1 mg/kg) tested [14].
Orally administered elobixibat is minimally absorbed
from the GI tract with picomolar levels found in plasma,
an expected half-life (t½) in humans of <4 h and no me-
tabolites detectable in human plasma. Given its low bio-
availability in plasma, it is expected that its action
reflects local inhibition of IBAT. In a multiple ascending
dose study (0.1–10 mg), administration of elobixibat was
found to be safe and tolerable across the dose levels
tested with no serious adverse events or discontinuations
[4] and in two Phase II studies in patients with CC, dose
levels of 5–10–15–20 mg have been evaluated with
beneficial effects on stool frequency, stool consistency
and symptoms of CC [3, 5].
Study participants
Eligible patients were men or non-pregnant women, 18–
80 years of age with a serum cholesterol of >5.5 mmol/l.
The body mass index ranged 18.5 up to 35. Major ex-
clusion criteria were: Known cardiovascular disease, s-
cholesterol > 8.5 mmol/l, s-triglycerides > 4.0 mmol/l,
use of drugs known to alter lipids and/or BAs within
12 weeks of screening visit, patients meeting the cri-
teria for diagnosis of IBS-D by Rome III standards [15]
or had any IBS associated symptoms and/or reported
loose (mushy) or watery stools during the 12 weeks
prior to the screening visit; exception being short term
(<5 days) of gastroenteritis.
Outcome measures
The primary end point of the study was the change in
LDL (low density lipoprotein) cholesterol from baseline to
day 28 of treatment. Secondary efficacy end points in-
cluded changes from baseline in total cholesterol, HDL
(high density lipoprotein) cholesterol, LDL/HDL ratio and
total triglycerides to Day 14 and to Day 28 of treatment
and C4 evaluation was used as the pharmacodynamic
marker of bile acid metabolism. The safety end points in-
cluded changes from baseline in the nature, incidence and
severity of AEs, clinical laboratory abnormalities and
changes over time in these parameters, vital signs, ECG
and physical findings.
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An intention to treat (ITT) analysis of all randomized
subjects was used as the primary analysis. Patients were
randomized in a 1:1:1 ratio to the treatment groups. For
the primary end point, the sample size selected yielded a
power of 80 % with a least significant difference between
treatment groups for LDL cholesterol of 0.4. All efficacy
end points were analyzed using the Wilcoxon rank sum
test and a two-sided p-value of <0.05 was considered sig-
nificant. No adjustment for multiplicity was performed.
Laboratory analyses
Conventional safety laboratory parameters including
serum glucose and liver function tests were evaluated in
both studies. No difference between the active groups
and placebo were identified. Assay of plasma lipopro-
teins LDL, HDL and total cholesterol and total triglycer-
ides were made using routine clinical methods.
Samples for fasting serum C4 were taken at approxi-
mately 8 am and measurements were conducted using
high-performance liquid chromatography, as previously
described [8].
The chronic constipation study
Study design, baseline eligibility, randomization, medication
The demographics and the results pertaining to effi-
cacy in CC and the safety of elobixibat at high dose
levels 15 mg and 20 mg/day have been reported [5]. In
brief, 36 female patients with CC were included in a
14 day treatment study to evaluate colonic transit and
constipation, 15 mg, 20 mg/day or placebo were ad-
ministered for 14 days. Serum samples were obtained
at baseline, in the morning Day 12 and throughout Day
12 (every 30 min for 2 h and then every hour up to
480 min after drug administration). Patients were ad-
ministered standardized meals; breakfast immediately
after the baseline sample, and a light lunch four hrs
after baseline sampling. Total GLP-1 concentrations in
plasma were measured by radioimmunoassay after ex-
traction of plasma with 70 % ethanol (vol/vol, final
concentration) using antiserum 89390 which has an
absolute requirement for the intact amidated carboxy-
terminus of GLP-1 7–36 amide and crossreacts fully
with GLP-1 9–36 amide, the primary metabolite of
dipeptidyl-peptidase −4 mediated degradation. The
sum of the two components (total GLP-1 concentra-
tion) reflects the rate of secretion of the L-cell. Sensi-
tivity was below 1 pmol/l, and intra-assay coefficient of
variation below 5 % [16] (16).
Results are reported as means ± standard error of the
mean (SEM) unless otherwise stated. For the analysis of
GLP-1, ANCOVA or ANOVA were used depending on
whether response or difference vs baseline were evalu-
ated. Comparisons were made between fasting value atstart of treatment to fasting value on Day 12 of treat-
ment and comparison of maximum (peak) value on Day
12 vs. at treatment allocation with fasting value before
treatment as covariate. Values of the area under the
curve (AUC) of serum GLP-1 concentrations were cal-
culated using the trapezoidal rule to assess the inte-
grated response of GLP-1 over 480 min. Statistical
analyses are based on t-test/Wilcoxon as indicated in the
Figures. Reporting of the studies conform to
CONSORT-revised and the EQUATOR guidelines [17].
Results
Results of the dyslipidemia study
Patient flow and follow-up
The study flow and patient demographics is shown in
Fig. 1. Out of 81 screened subjects, 36 patients fulfilled
eligibility criteria, entered the study and were random-
ized to treatment with elobixibat or placebo. All patients
completed the study; the ITT and the Safety population
include the same patients. At baseline, the demographic
parameters were similar between the treatment groups
(Table 1A). Patients had a mean age of 63 years (range
34–80) and there was a slight preponderance for women
(58 %). Baseline lipid profiles were similar across the
groups (Table 1A). No changes in safety laboratory
values, including liver enzymes and plasma glucose, were
identified during the study.
Effects of elobixibat on lipid profiles and on C4
There was a significant (p = 0.044) change from baseline
to end of treatment in LDL cholesterol (7.4 %) for the
5 mg elobixibat treatment group – the primary end
point of the study (Fig. 2). No significant change was
achieved for the 2.5 mg elobixibat cohort. When analyz-
ing the mean and median change values from baseline
to Days 14 and 28, there was a more prominent reduc-
tion in the drug-treated groups as compared to placebo
whereas on day 42 (14 days after cessation of treatment)
there was no clear difference.
Elobixibat treatment did not significantly alter total
cholesterol, HDL cholesterol or triglycerides (Fig. 2). In
contrast, the LDL/HDL ratio was significantly reduced on
Day 28 in the 5 mg group (p = 0.004) (18 %) whereas no
effect was seen in the 2.5 mg group (p = 0.06) (Fig. 2).
C4 was significantly increased in both the 2.5 mg and
in the 5 mg elobixibat groups on Day 28 (p = 0.03 for
both groups) (Fig. 3).
Safety assessments
No serious adverse events (SAEs) were reported during the
dyslipidemia study. AEs were most prevalent in the placebo
group (92 % of the patients reported 27 AEs). In the 2.5 mg
and 5 mg treatment groups, 50 % and 67 % of the patients
reported a total of 11 and 14 AEs respectively. Most of the
Subjects randomized
           n=36
   Subjects receiving
double blind medication
           n=36
Withdrawn
     n=0
Withdrawn
     n=0
Withdrawn
     n=0
Completed
   n=12
Completed
   n=12
Completed
   n=12
Subjects receiving
  2.5 mg A3309
         n=12
Subjects receiving
     5 mg A3309
         n=12
Subjects receiving
       Placebo
         n=12
Subjects screened
           n=81
            Screen failures
n=45
(consent not given or withdrawn -3;
All eligibility criteria not fulfilled -42
Fig. 1 Patient flow chart in the Dyslipidemia study
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were moderate, two in the placebo group and two in the
5 mg group; none of them were judged to be related to the
study drug. No patient discontinued the study. Table 2 out-
lines the incidence of AEs. The most common AEs were
headache, diarrhea and constipation. Notably, diarrhea was
reported in 3 patients on placebo, 2 patients on 2.5 mg and
3 patients on 5 mg.Table 1 Demographics and baseline parameters
A. Dyslipidemia study
Placebo (N = 12
Female n (%) 8 (66.7)
Caucasian n (%) 12 (100.0)
Age (years) Mean (SD) 64.4 (10.1)
Weight (kg) Mean (SD) 76.2 (16.3)
BMI (kg/m2) Median 24.8
LDL-Cholesterol (mmol/L) Mean (SD) 4.29 (0.71)
Cholesterol (mmol/L) Mean (SD) 6.38 (0.75)
HDL-Cholesterol (mmol/L) Mean (SD) 1.53 (0.49)
LDL/HDL-Cholesterol (mmol/L) Mean (SD) 3.00 (0.92)
B. The CC study
Placebo (N = 13
Female n (%) 13 (100.0)
Caucasian n (%) 11 (92.3)
Age (years) Mean (SD) 47.2 (9.30)
Weight (kg) Mean (SD) 70.2 (9.7)
BMI (kg/m2) Median 25.9
GLP-1 (pmol/L) Mean (SD) 18.45a (8.63)
an = 11
bn = 9Results of the CC study
Demographic parameters are described in Table 1B. Ef-
ficacy on pharmacodynamics and clinical endpoints of
CC and safety assessments have been reported previ-
ously [5].
No changes in safety laboratory values, including liver
enzymes and plasma glucose, were identified during the
study.) Elobixibat 2.5 mg (N = 12) Elobixibat 5 mg (N = 12)
7 (58.3) 6 (50.0)
12 (100.0) 12 (100.0)
60.9 (13.2) 62.7 (11.4)
78.1 (16.4) 76.6 (12.8)
26.3 26.4
4.61 (0.63) 4,78 (0.65)
6.44 (0.57) 6.57 (0.72)
1.34 (0.43) 1.23 (0.30)
3.77 (1.60) 4.32 (1.73)
) Elobixibat 15 mg (N = 12) Elobixibat 20 mg (N = 11)
12 (100.0) 11 (100.0)
12 (100.0) 12 (100.0)
38.3 (8.18) 46.1 (6.36)
72.9 (15.5) 75.0 (17.0)
24.8 26.0
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   Total
cholesterol
    LDL-
cholesterol



























Fig. 2 Median % changes (interquartile 25–75 % range) from
baseline for plasma total cholesterol, LDL, HDL, LDL/HDL ratio
and triglycerides (TG) in the Dyslipidemia study. *: p = 0.044
**: p = 0.004 (Wilcoxon)
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constipated patients
Peak values for GLP-1 levels increased significantly dur-
ing the day, when adjusted for baseline values, for both
the 15 mg (20.7 ± 2.4 pmol/L) and the 20 mg (25.6 ± 4.9
pmol/L) groups (p = 0.03 and p = 0.02 respectively) com-
pared with placebo (12.8 ± 2.4 pmol/L) (Fig. 4). Peak
values were observed at lunch time. No significant dif-
ferences were observed for the basal morning levels at
Day 12 of treatment when compared to levels prior to
treatment. Similarly, there were no significant differences
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Fig. 3 Median % changes (interquartile 25–75 % range) from
baseline for plasma C4 in the Dyslipidemia study. *: p <0.03 (Wilcoxon)pmol/L*hr (15 mg), 225 ± 27 pmol/L*hr (20 mg) and
180 ± 27 pmol/L*hr (placebo).
Discussion
The current results provide insight in metabolic re-
sponses obtained when administering an IBAT inhibitor
to dyslipidemic patients with elevated cholesterol levels,
and when employed at high dose to patients with CC. At
a dose of 5 mg elobixibat reduced LDL cholesterol by
7.4 % and decreased the LDL/HDL ratio by 18 %. The
reduced LDL/HDL ratio is of particular interest since it
is an important risk factor for the development of car-
diovascular disease (CVD) [18]. The beneficial effects of
elobixibat on serum lipids confirm previous findings by
Chey et al. [3]. A limitation of this paper is the fact that
data have been collected from two different populations
(patients with dyslipidemia or with chronic constipa-
tion). It would have been of interest to assess GLP-1 in
patients with dyslipidemia as well and to perform a thor-
ough analysis of subfractions of LDL and HDL but given
the set-up of the study, this was not possible due to re-
strictions in the sampling.
Although no patient discontinued the study, signs of
increased colonic transit were identified (Table 2). On
the other hand, the improved LDL/HDL ratio should be
beneficial in patients with CC. This because it has been
reported that constipation is a risk factor for CVD
events [19] as shown from women with severe constipa-
tion having a 23 % higher risk for CVD events, and an
unadjusted risk of death due to CVD almost five-fold
higher: 3.25 (95 % CI 1.76–5.01) in severe constipation
as compared to 0.76 (95 % CI 0.54–1.06)/1000 person-years
in subjects without constipation. Moreover, Salmoirago
et al. [19] reported that the more severe state of consti-
pation at baseline, the more frequent is the use of
cholesterol-lowering medication. Further support for a
relation between atherosclerosis and constipation was
found in a study [20] on patients with known CVD
having a 2.5-fold higher prevalence of constipation as
compared to subjects without constipation. Cholesterol
is to a great extent eliminated from the body through
fecal loss of BAs [21] (21) that is clearly reduced in pa-
tients with CC [22–24]. Interestingly, also in patients
with CVD, fecal BA excretion is significantly reduced
as compared with non-CVD patients [25].
Considering the above findings, it is conceivable that
an IBAT inhibitor like elobixibat administered for the
treatment of CC may be particularly attractive not only
to relieve symptoms of constipation but also to lower
LDL cholesterol and reduce the increased risk for CVD
observed in subjects with constipation.
The significantly increased levels of GLP-1 in re-
sponse to a dose level of elobixibat approximately twice
the target dose for patients with CC suggests that IBAT
Table 2 Adverse events occurring in more than one subject in the Dyslipidemia study. No serious adverse events and no
discontinuations were identified
Placebo (N = 12) A3309 - 2.5 mg (N = 12) A3309 - 5 mg (N = 12)
MedDRA system organ class MedDRA preferred term n (%) n (%) n (%)
Gastrointestinal disorders Abdominal distension 1 (8.3) 1 (8.3) 1 (8.3)
Constipation 4 (33.3) 1 (8.3) -
Diarrhoea 3 (25.0) 2 (16.7) 3 (25.0)
General disorders and administration site conditions
Pyrexia 1 (8.3) - 1 (8.3)
Infections and infestations
Pharyngitis 1 (8.3) - 1 (8.3)
Rhinitis 2 (16.7) - -
Musculoskeletal and connective tissue disorders Myalgia 2 (16.7) - -
Nervous system disorders Dizziness 2 (16.7) - -
Headache 3 (25.0) 3 (25.0) 3 (25.0)
Renal and urinary disorders Polyuria 1 (8.3) 1 (8.3) -
Respiratory, thoracic and mediastinal disorders Cough 1 (8.3) - 1 (8.3)
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through elevated BAs in the intestine interacting with
TGR5 receptors, thereby stimulating synthesis and se-
cretion of GLP-1 [6, 7, 9, 26, 27]. As compared to treat-
ment with DPP-4 inhibitors, the meal-induced plasma
GLP-1 levels with elobixibat treatment are smaller [28].
However, it is important to point out that the meal
stimulus in this study was a standardized low calorie
chicken breast lunch, and that GLP-1 AUC measure-
ments were evaluated over a longer time period, most
likely inducing a lower response than a high calorie load
or an oral glucose tolerance test.
The most commonly used drug in T2DM, metfor-
min, probably in part acts through enhancing GLP-1
secretion [28]. This effect may be mediated through
































15 mg    (n=12)
20 mg  (n=11)
*
Fig. 4 GLP-1 (pmol/L) in the CC study. Data shown are the
difference between peak values Day 12 and the basal pre-study
value. Mean ± SEM. *: p < 0.05 (Wilcoxon)active BA absorption from the ileum [11]. Although
data are not uniform [29] other IBAT-inhibitors have
demonstrated incretin-releasing properties in animals
[30]. Intriguingly, BA sequestrants like cholestyramine
bind BAs and therefore reduce free BAs in the colon,
have been reported beneficial in T2DM [31]. Results
have shown that colesevelam when bound to BAs may acti-
vate TGR-5 receptors in vitro [10]. On the other hand, in
healthy humans cholestyramine-induced changes of serum
glucose can appear independent of serum GLP-1 levels
(Rudling M, unpublished research).
The positive effects of IBAT-inhibition on GLP-1 secre-
tion may thus be particularly beneficial in CC patients with
T2DM or pre-diabetes; two disease entities associated with
increased risk for constipation [18, 32, 33].Conclusion
In summary, the studies reported here provide evi-
dence of decreased LDL cholesterol and increased
GLP-1 levels when using elobixibat in patients with
dyslipidemia and with CC respectively; these effects
are consistent with metabolic effects of BAs in the ileo-
colonic region in humans. Further development of
IBAT-inhibitors to combat metabolic disease will pos-
sibly be restricted by the effects of IBAT inhibition on
colonic transit, resulting in diarrhea. However, given
the association between symptoms of constipation with
cardiovascular disease and T2DM, it seems that an
IBAT inhibitor like elobixibat, in addition to positive
effects on symptoms and signs of constipation, may
provide positive metabolic side effects reducing the
risk for CVD and T2DM.
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